Stubblefield P G
Department of Obstetrics and Gynecology, Maine Medical Center, Portland 04102.
Am J Obstet Gynecol. 1993 Mar;168(3 Pt 2):1047-52. doi: 10.1016/0002-9378(93)90336-h.
Epidemiologic research has shown that current low-dose estrogen oral contraceptives are associated with a low risk of vascular events (e.g., myocardial infarction, stroke, and venous thrombosis or thromboembolism). Yet questions still persist about the effects of low-dose oral contraceptives on the cardiovascular system. Changes in the coagulation system have been linked primarily to the estrogen component; however, it has been proposed that the progestin may have an influence on the fibrinolytic system. Desogestrel, a new gonane progestin, has been commercially available in Europe since 1981. It has been widely shown to produce minimal changes of the coagulation and fibrinolytic systems, and it has not been associated with an increased risk of thromboembolic disorders.
流行病学研究表明，目前的低剂量雌激素口服避孕药与血管事件（如心肌梗死、中风以及静脉血栓形成或血栓栓塞）的低风险相关。然而，关于低剂量口服避孕药对心血管系统的影响仍然存在疑问。凝血系统的变化主要与雌激素成分有关；不过，有人提出孕激素可能对纤溶系统有影响。去氧孕烯是一种新型孕烷类孕激素，自1981年起在欧洲上市。大量研究表明，它对凝血和纤溶系统产生的变化极小，并且与血栓栓塞性疾病风险增加无关。
